Axsome
Manufacturing · New York, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1 World Trade Ctr Fl 29, New York, New Y...Phone Number
(212) 332-3241Website
www.axsome.comRevenue
$708.2 MillionStock Symbol
AXSMIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
2
2
1
1
About Axsome
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to developing products that meaningfully improve the lives of patients and provide additional therapeutic options for physicians.Explore more
Axsome Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Axsome your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Axsome is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Axsome had a recent Job posting/layoffs
Check if Axsome has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Axsome recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Axsome
Product Launch: Get notified when Axsome launches new products
Axsome, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Axsome has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Axsome
Compare insights from companies similar to Axsome, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$827.1M
501-1,000
Public
$2.5B
1998
QN
Quintus NgumahVice President, Clinical Development & Chief Marketing Officer, Cos To The
Company Profile Activity
Activity Insights
Axsome is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Axsome is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Axsome.
Axsome financials insights
Gather financial insights about Axsome, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$3.7M
2014
Debt
$2M
Debt
$1.3M
2015
Debt
$2.5M
Stock Offering
$51M
2016
Debt
$20M
2025
Debt
$570M
Axsome Tech Stack
A closer look at the technologies used by Axsome
Most Recent Scoops
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance, Financial Transactions
Project
Laboratory Operations, Medical Research, Clinical Operations
Axsome News & Media
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
FDA sets PDUFA target action date of May 1, 2027Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2026 on Monday, August 10, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provideAxsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHDIs Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say.
The stock has soared more than 220% in three years.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Axsome
Sign Up For FreeTo access detailed company insights
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are intensely committed to develop... Read More
